Attached files
Exhibit
32
CERTIFICATION PURSUANT TO
18 USC, SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In
connection with this amended quarterly report of Sunshine
Biopharma, Inc. (the “Company”) on Form
10-Q/A for the six month period ended June 30, 2020,
as filed with the Securities and Exchange Commission on August 18,
2020 (the “Report”), we, the undersigned, in the
capacities and on the date indicated below, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that to the best of our
knowledge:
1.
The Report fully
complies with the requirements of Rule 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
2.
The information
contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the
Company.
Dated:
August 28, 2020
|
s/ Dr.
Steve N. Slilaty
Dr.
Steve N. Slilaty, Chief Executive Officer
|
|
|
Dated:
August 28, 2020
|
s/
Camille Sebaaly
Camille
Sebaaly, Chief Financial Officer
|